An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism
- 17 August 2020
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (9) , 973-988
Abstract
Acute myeloid leukemia (AML) is an aggressive malignancy of clonal myeloid precursor cells. Curative therapy has classically involved the use of intensive induction chemotherapy followed by consoli...Keywords
This publication has 154 references indexed in Scilit:
- Raise standards for preclinical cancer researchNature, 2012
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- Bromodomains as therapeutic targetsExpert Reviews in Molecular Medicine, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- The Tumor Suppressor p53: From Structures to Drug DiscoveryCold Spring Harbor Perspectives in Biology, 2010
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002